XTL Biopharmaceuticals Ltd (XTLB) - Total Liabilities

Latest as of December 2024: ILA3.12 Million ILA ≈ $8.35K USD

Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) has total liabilities worth ILA3.12 Million ILA (≈ $8.35K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore XTL Biopharmaceuticals Ltd equity growth rate to track the company's year-over-year net asset growth rate.

XTL Biopharmaceuticals Ltd - Total Liabilities Trend (2013–2024)

This chart illustrates how XTL Biopharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data.

XTL Biopharmaceuticals Ltd Competitors by Total Liabilities

The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Sego Resources Inc V:SGZ	Canada	CA$470.19K
Optima Prima Metal Sinergi JK:OPMS	Indonesia	Rp1.45 Billion
GreenPower Motor Company Inc NASDAQ:GP	USA	$40.31 Million
Ravi Kumar Distilleries Limited NSE:RKDL	India	Rs886.28 Million
Silver Elephant Mining Corp TO:ELEF	Canada	CA$6.85 Million
Nandani Creation Limited NSE:JAIPURKURT	India	Rs623.08 Million
COMTEC SOLAR SYS HD -004 F:8C11	Germany	€306.68 Million
PAVmed Inc NASDAQ:PAVM	USA	$12.28 Million

Liability Composition Analysis (2013–2024)

This chart breaks down XTL Biopharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see XTL Biopharmaceuticals Ltd stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.61	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.57	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.36	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XTL Biopharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XTL Biopharmaceuticals Ltd (2013–2024)

The table below shows the annual total liabilities of XTL Biopharmaceuticals Ltd from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	ILA3.12 Million ≈ $8.35K	+1412.14%
2023-12-31	ILA206.00K ≈ $552.28	+10.16%
2022-12-31	ILA187.00K ≈ $501.34	-85.45%
2021-12-31	ILA1.28 Million ≈ $3.45K	+405.91%
2020-12-31	ILA254.00K ≈ $680.97	+9.48%
2019-12-31	ILA232.00K ≈ $621.98	-8.30%
2018-12-31	ILA253.00K ≈ $678.28	-91.47%
2017-12-31	ILA2.97 Million ≈ $7.95K	+799.09%
2016-12-31	ILA330.00K ≈ $884.72	-24.31%
2015-12-31	ILA436.00K ≈ $1.17K	-54.82%
2014-12-31	ILA965.00K ≈ $2.59K	-21.54%
2013-12-31	ILA1.23 Million ≈ $3.30K	--

About XTL Biopharmaceuticals Ltd

TA:XTLB Israel Biotechnology

Market Cap

$4.96 Million

ILA1.85 Billion ILA

Market Cap Rank

#28566 Global

#417 in Israel

Share Price

ILA2.10

Change (1 day)

-4.55%

52-Week Range

ILA1.60 - ILA8.70

All Time High

ILA14.98